It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Sandoz: A leader in patient access, savings, and manufacturing1-6

Sandoz is a proven leader

First biosimilar to surpass its reference product in market share7

  • More than 27 million patient-exposure days in 100 countries7,8
  • ZARXIO has the most unrestricted combined medical and pharmacy benefit coverage in the SA G-CSF class9*
  • Demonstrated cost-effectiveness as primary prophylaxis to decrease the incidence of chemotherapy-induced febrile neutropenia in cancer patients2,7
  • Real-world evidence of savings across IDNs, payers, and patients6,10-12

*"Most" defined as a comparison to Neupogen®, Granix®, and Nivestym® in terms of combined medical and pharmacy benefit status. "Unrestricted" defined as on formulary, managed to Prescribing Information, and not requiring prior authorization and step edits. Coverage defined as "Exclusive or Co-Preferred" on commercial, Medicare, health exchange plans, and pharmacy benefit managers (PBMs) on pharmacy benefit, and commercial, Medicare, and health exchange plans on medical benefit according to Managed Markets Insight & Technology (MMIT) data as of June 2018.9

ZARXIO cost savings may liberate healthcare resources and expand patient access

~$1.6 billion savings were driven by biosimilar filgrastim2†

Cost savings chart
Zarxio Cost Savings Chart

Biosimilars allow for expanded patient access and significant savings for patients, helping alleviate the overburdened healthcare system2

Sandoz is committed to bringing biosimilars to more patients around the world

  • Strong investment in manufacturing: End-to-end technical capabilities ensure the reliable development, manufacturing, and supply of industry-leading, quality biosimilars
  • Robust pipeline: With 8 approved biosimilars in Europe, as well as a strong development pipeline, Sandoz will continue to leverage its global expertise in the US13
  • Proven track record: First company to bring biosimilars to patients in both the US and worldwide1,14

Learn about Ziextenzo (pegfilgrastim-bmez), the long-acting G-CSF treatment option from Sandoz15

G-CSF=granulocyte colony-stimulating factor; IDN=integrated delivery network; SA=short-acting.

Neupogen is a registered trademark of Amgen Inc.
Granix is a registered trademark of Teva Pharmaceutical Industries Ltd.
Nivestym is a registered trademark of Pfizer Inc.

References: 1. FDA approves first biosimilar product Zarxio [press release]. US Food and Drug Administration; March 6, 2015. Accessed January 13, 2021. 2. Data on file. Filgrastim Net Sales Analysis Model. Sandoz Inc. April 2021. 3. Wang W, Campbell K, Balu S. Cost-minimization analysis for biosimilar pegfilgrastim in the prophylaxis of chemotherapy induced (febrile) neutropenia and expanded access based on budget neutral basis. J Clin Oncol. 2019;37(suppl 15):6645. doi:10.1200/JCO.2019.37.15_suppl.6645. 4. US Food and Drug Administration. Presented at: FDA Oncologic Drugs Advisory Committee Meeting; January 7, 2015. 5. Data on file. Novartis Manufacturing Manual Version 2.0. Sandoz Inc. 6. Puckrein G, Xu Liu, Ryan A, Campbell K, Balu S. Potential Medicare beneficiary out-of-pocket reductions through using biosimilar filgrastim-sndz over reference filgrastim: a simulation analysis. Poster presented at: AMCP Nexus; October 22–25, 2018; Orlando, Florida. 7. Data on file. Zarxio and Ziextenzo Market Share Analysis. Sandoz Inc. October 2020. 8. Data on file. Sandoz Biosimilar PSUR Data. Sandoz Inc. February 2021. 9. Data on file. Zitter Raw Data. October 2017. 10. Data on file. Zarxio Sales WAC Pricing. Sandoz Inc. November 2020. 11. Trautman H, Szabo E, James E, Tang B. Patient-administered biologic and biosimilar filgrastim may offer more affordable options for patients with nonmyeloid malignancies receiving chemotherapy in the United States: a budget impact analysis from the payer perspective. J Manag Care Spec Pharm. 2019;25(1):94-101. doi:10.18553/jmcp.2018.18094. 12. Data on file. IDN Qualitative Insights Series Presentation created by Zitter Health Insights. Sandoz Inc. 2018. 13. Columbus G. Pegfilgrastim biosimilar approved in Europe. OncLive website. Published November 27, 2018. Accessed January 15, 2021. 14. Data on file. Periodic Safety Update Report (PSUR) for somatropin – containing products, April 1, 2017 ⎼ September 30, 2017. Sandoz Inc. November 2017. 15. ZIEXTENZO Prescribing Information. Sandoz Inc. March 2021.